<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of low-dose Ara C (LD-Ara C) (10 mg/m2 q 12 hr s.c.) for a minimum of 10 days was evaluated in 21 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 15 patients with <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">dysmyelopoietic syndromes</z:e> (<z:chebi fb="0" ids="888">DMPS</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>Median age (range) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-patients was 47 yrs (19-89), and for <z:chebi fb="0" ids="888">DMPS</z:chebi>-patients 60 (22-78) </plain></SENT>
<SENT sid="2" pm="."><plain>From the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-group, 9 patients were either primary refractory or resistant to intensive re-induction treatment of relapse, 6 others had heavy pretreatment, 1 suffered from <z:e sem="disease" ids="C0026987" disease_type="Neoplastic Process" abbrv="">myelosclerosis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-patients had no pretreatment at first presentation and were started on LD-Ara C because of old age (3) or poor condition (2) including 1 patient with a secondary <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="888">DMPS</z:chebi> included those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (8) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (7) </plain></SENT>
<SENT sid="5" pm="."><plain>12 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and 4 with <z:chebi fb="0" ids="888">DMPS</z:chebi> displayed a <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> of greater than 10 X 10(9)/l </plain></SENT>
<SENT sid="6" pm="."><plain>Three out of 21 AML-patients reached complete remission (CR), one of them twice, with partial remission (PR) at the third attempt with this type of treatment </plain></SENT>
<SENT sid="7" pm="."><plain>Two other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-patients reached a P.R. of 5 and 1 months duration respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients experienced a transient response characterized by improved peripheral blood counts and cessation of transfusion requirements, one of them for 12 months </plain></SENT>
<SENT sid="9" pm="."><plain>In 5 AML-patients no effect was seen and 8 pts. died </plain></SENT>
<SENT sid="10" pm="."><plain>In the <z:chebi fb="0" ids="888">DMPS</z:chebi>-group, 5/15 patients reached C.R., one patient twice with the same treatment, 1 patient reached a P.R., 1 improved, 6 showed no effect, and 2 died </plain></SENT>
<SENT sid="11" pm="."><plain>In 13 patients final examination of the bone marrow was not performed after treatment because of either early <z:hpo ids='HP_0011420'>death</z:hpo> or obvious progression </plain></SENT>
<SENT sid="12" pm="."><plain>Treatment was associated with significant, transient hematologic toxicity </plain></SENT>
<SENT sid="13" pm="."><plain>Patients suffering from <z:chebi fb="0" ids="888">DMPS</z:chebi> had prolonged <z:mpath ids='MPATH_58'>aplasia</z:mpath> and required more blood and platelet support than pts with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>Responding <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients had a rapid hematologic regeneration </plain></SENT>
<SENT sid="15" pm="."><plain>Considering the poor prognosis of both of our treatment groups, this therapeutic approach proved to be of considerable benefit </plain></SENT>
</text></document>